Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jan:160:282-284.
doi: 10.1016/j.ejca.2021.09.048. Epub 2021 Oct 28.

Letter comments on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single-centre prospective study: Interaction between lymphopenia and anti-SARS-CoV-2 antibodies after two injections of the Pfizer-BioNTech vaccine in patients with cancers treated by chemotherapy or immunotherapy

Sakina Sekkate  1 , Henri-Corto Stoeklé  2 , May Mabro  1 , David Billard  1 , Titouan Kennel  3 , Marc Vasse  4 , Christian Hervé  5 , Philippe Beuzeboc  6
Affiliations
Comment

Letter comments on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single-centre prospective study: Interaction between lymphopenia and anti-SARS-CoV-2 antibodies after two injections of the Pfizer-BioNTech vaccine in patients with cancers treated by chemotherapy or immunotherapy

Sakina Sekkate et al. Eur J Cancer. 2022 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement None declared.

Figures

Fig. 1
Fig. 1
Correlation between antibody and lymphocyte levels.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Shmueli E.S., Itay A., Margalit O., Berger R., Halperin S., Jurkowicz M., et al. Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy – a single centre prospective study. Eur J Cancer. 2021;157:124–131. - PMC - PubMed
    1. Goshen-Lago T., Waldhorn I., Holland R., Szwarcwort-Cohen M., Reiner-Benaim A., Shachor-Meyouhas Y., et al. Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer. JAMA Oncol. 2021;7(10):1507–1513. doi: 10.1001/jamaoncol.2021.2675. - DOI - PMC - PubMed
    1. Barrière J., Chamorey E., Adjtoutah Z., Castelnau O., Mahamat A., Marco S., et al. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors. Ann Oncol. 2021;32(8):1053–1055. - PMC - PubMed
    1. Monin L., Laing A.G., Muñoz-Ruiz M., McKenzie D.R., del Molino del Barrio I., Alaguthurai T., et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22(6):765–778. - PMC - PubMed
    1. Stoeklé H.-C., Sekkate S., Angellier E., Hervé C., Beuzeboc P. Refusal of anti-coronavirus disease 2019 vaccination in cancer patients: is there a difference between the sexes? Eur J Cancer. 2021;155:54–55. - PMC - PubMed